topotecan hydrochloride for injection

DRUG5 trials

Sponsors

Telik, MediLink Therapeutics (Suzhou) Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., SUNHO（China）BioPharmaceutical CO., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Conditions

Metastatic Cervical CancerOvarian CancerOvarian NeoplasmsRecurrent Cervical CancerSmall Cell Lung Cancer

Phase 2

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

Not yet recruitingNCT07076095

SUNHO（China）BioPharmaceutical CO., Ltd.Small Cell Lung Cancer

Start: 2025-08-01End: 2031-08-01Target: 200Updated: 2025-07-21

Phase 3

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

CompletedNCT00057720

TelikOvarian Neoplasms

Start: 2003-06-30End: 2006-12-31Target: 440Updated: 2011-07-25

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

RecruitingNCT06612151

MediLink Therapeutics (Suzhou) Co., Ltd.Small Cell Lung Cancer

Start: 2024-12-17End: 2030-12-01Target: 438Updated: 2025-02-11

A Study of SHR-A1811 in Subjects With Ovarian Cancer

RecruitingNCT06828354

Jiangsu HengRui Medicine Co., Ltd.Ovarian Cancer

Start: 2025-03-13End: 2027-12-31Target: 300Updated: 2025-03-24

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

Not yet recruitingNCT07418749

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Metastatic Cervical Cancer, Recurrent Cervical Cancer

Start: 2026-03-01End: 2028-12-01Target: 398Updated: 2026-02-18

Related Papers

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Nature Medicine2025-03-1336 citations